妊娠特有肝病诊治进展

doi:10.3969/j.issn.1672-5069.2021.03.037

Abstract

Abstract: There are normal physiological changes in the liver functions during pregnancy. Nevertheless, 3% of pregnant women have liver dysfunction. Pregnancy-specific liver disease is the main cause of abnormal liver function. About 0% to 25% of pregnant women die from pregnancy-specific liver disease. It is particularly important to improve clinician’s recognition of this entity. We reviewed the literature on pregnancy-specific liver disease in recent years and the progress in the pathogenesis, diagnosis and treatment of some pregnancy-specific liver diseases was summarized in this paper, in order to provide reference for its diagnosis and treatment.

Key words: Pregnancy-related liver diseases, Diagnosis, Treatment

Zhu Lin, Qin Gang. Progress in diagnosis and treatment of patients with pregnancy-specific liver disease[J]. Journal of Practical Hepatology, 2021, 24(3): 449-452.

References

[1] 中华医学会妇产科学分会产科学组. 妊娠剧吐的诊断及临床处理专家共识(2015). 中华妇产科杂志, 2015, 50(11): 801-804.
[2]ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy. Obstet Gynecol, 2018, 131(1): e15-e30.
[3] Fejzo MS, Trovik J, Grooten IJ, et al. Nausea and vomiting of pregnancy and hyperemesis gravidarum. Nat Rev Dis Primers, 2019, 5(1): 62.
[4] ACOG Practice Bulletin No. 153: Nausea and Vomiting of Pregnancy. Obstet Gynecol, 2015, 126(3): e12-24.
[5] Niemeijer MN, Grooten IJ, Vos N, et al. Diagnostic markers for hyperemesis gravidarum: a systematic review and metaanalysis. Am J Obstet Gynecol, 2014, 211(2): 150 e151-115.
[6] Fejzo MS, Sazonova OV, Sathirapongsasuti JF, et al. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nat Commun, 2018, 9(1): 1178.
[7] Hsu JY, Crawley S, Chen M, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature, 2017, 550(7675): 255-259.
[8] Fejzo MS, Fasching PA, Schneider MO, et al. Analysis of GDF15 and IGFBP7 in Hyperemesis Gravidarum Support Causality. Geburtshilfe Frauenheilkd, 2019, 79(4): 382-388.
[9] 中华医学会妇产科学分会产科学组. 妊娠期肝内胆汁淤积症诊疗指南(2015). 中华妇产科杂志, 2015, 50(7): 481-485.
[10] Manzotti C, Casazza G, Stimac T, et al. Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy. Cochrane Database Syst Rev, 2019, 7: CD012546.
[11] Ma L, Zhang XQ, Zhou DX, et al. Feasibility of urinary microRNA profiling detection in intrahepatic cholestasis of pregnancy and its potential as a non-invasive biomarker. Sci Rep, 2016, 6: 31535.
[12] Jiang PY, Zhu XJ, Jiang RA, et al. MicroRNAs derived from urinary exosomes act as novel biomarkers in the diagnosis of intrahepatic cholestasis of pregnancy. Am J Transl Res, 2019, 11(9): 6249-6261.
[13] Chen Z, Shen Z, Hu L, et al. Identification of Matrix Metalloproteinase-2 and 9 as Biomarker of Intrahepatic Cholestasis of Pregnancy. Ann Hepatol, 2017, 16(2): 291-296.
[14] Chappell LC, Bell JL, Smith A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet, 2019, 394(10201): 849-860.
[15] Ovadia C, Seed PT, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet, 2019, 393(10174): 899-909.
[16] You S, Cui AM, Hashmi SF, et al. Dysregulation of bile acids increases the risk for preterm birth in pregnant women. Nat Commun, 2020, 11(1): 2111.
[17] Puljic A, Kim E, Page J, et al. The risk of infant and fetal death by each additional week of expectant management in intrahepatic cholestasis of pregnancy by gestational age. Am J Obstet Gynecol, 2015, 212(5): 667 e661-665.
[18] Brown MA, Magee LA, Kenny LC, et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension, 2018, 72(1): 24-43.
[19] 中华医学会妇产科学分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊治指南(2015). 中华产科急救电子杂志, 2015, (4): 206-213.
[20] Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med, 2016, 374(1): 13-22.
[21] Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J, 2018, 39(34): 3165-3241.
[22] Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet, 2019, 145 Suppl 1: 1-33.
[23] Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med, 2017, 377(7): 613-622.
[24] ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol, 2019, 133(1): e1-e25.
[25] Sasmaz MI, Ayvaz MA, Dulger AC, et al. Aspartate-aminotransferase to platelet ratio index score for predicting HELLP syndrome. Am J Emerg Med, 2019.
[26] Schnabel A, Blois SM, Meint P, et al. Elevated systemic galectin-1 levels characterize HELLP syndrome. J Reprod Immunol, 2016, 114: 38-43.
[27] Munoz-Hernandez R, Medrano-Campillo P, Miranda ML, et al. Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome. Am J Hypertens, 2017, 30(7): 673-682.
[28] Woudstra DM, Chandra S, Hofmeyr GJ, et al. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev, 2010, (9): CD008148.
[29] Goel A, Ramakrishna B, Zachariah U, et al. How accurate are the Swansea criteria to diagnose acute fatty liver of pregnancy in predicting hepatic microvesicular steatosis? Gut, 2011, 60(1): 138-139; author reply 139-140.
[30] Morikawa M, Kawabata K, Kato-Hirayama E, et al. Liver dysfunction in women with pregnancy-induced antithrombin deficiency. J Obstet Gynaecol Res, 2017, 43(2): 257-264.

Progress in diagnosis and treatment of patients with pregnancy-specific liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Pei Xudong, Zhang Xiaohu, Chu Guike, et al. Preliminary observation on clinical efficacy of Xiaozhi Quzhuo decoction in the treatment of patients with nonalcoholic simple fatty liver [J]. Journal of Practical Hepatology, 2021, 24(3): 355-358.
[2]	Jia Qunling, Xu Zhibin, Han Shu. Implication of magnetic resonanceimaging-proton density fat fraction in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 359-362.
[3]	Nan Dong, Hong Jinling, Jiang Haiyu. Efficacyof DCE-MRI in evaluating severity of gastroesophageal varices in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(3): 407-410.
[4]	Wang Yaozheng, Wang Yulin, Lin Yi. Diagnostic efficacy of ¹⁸F-FDG PET/CT scan in patients with ntrahepatic cholangiocarcinoma [J]. Journal of Practical Hepatology, 2021, 24(3): 427-430.
[5]	Gan Yanying, Zhong Kai, Guan Yanling, et al. Diagnostic efficacy of ultrasonography,CT and MRCP in the diagnosis of extrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2021, 24(3): 439-442.
[6]	Bai Jie, Zheng Sujun. Focus on the study of patients with inherited metabolic liver disease [J]. Journal of Practical Hepatology, 2021, 24(2): 153-155.
[7]	Zhang Siwei, Kong Yin, Liu Tianfu, et al. Predictive value of histological activity index and fibrosis by liver stiffness measurement and ICGR15 in patients with hepatitis B and normal or minimally elevated serum ALT levels [J]. Journal of Practical Hepatology, 2021, 24(2): 184-187.
[8]	Dai Haifeng, Wang Tian, Lei Xun, et al. Diagnosticefficacy of transient elastography in combination with APRI and AAR in evaluating significant liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(2): 196-199.
[9]	Yang Zhenhui, Gu Baohuan, Dai Xiaoling. Early screening of nonalcoholic steatohepatitis by FibroScan with liver controlled attenuation parameters [J]. Journal of Practical Hepatology, 2021, 24(2): 212-215.
[10]	Xu Chunling, Miao Chongchang, Liu Yucheng, et al. Clinicalimplications of MRI multi-echo dixon technique in diagnosing hepatic steatosis in patients with metabolic associated fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(2): 220-223.
[11]	Wang Ruoyu, Wu Yunan, Tang Dan. Diagnostic value of plasma Ki67 and miRNA-26b levels in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(2): 264-267.
[12]	Dai Xiaobing, Liu Qiyu, Wu Junhui. Diagnosis of focal lesions of liver by diffusion-weighted magnetic resonance imaging [J]. Journal of Practical Hepatology, 2021, 24(2): 268-271.
[13]	Chen Jiaojiao, He Nian’an, Fang Jing, et al. Conventionaland contrast-enhanced ultrasonography manifestations of intrahepatic cholangiocarcinoma [J]. Journal of Practical Hepatology, 2021, 24(2): 272-275.
[14]	Song Bin, Zhao Houliang, Ye Li. Application of three-dimensional magnetic resonance cholangiopancreatography in diagnosis of biliary atresia in children [J]. Journal of Practical Hepatology, 2021, 24(2): 288-291.
[15]	Wu Dongqiu,Cui Lihua,Xiong Feng,et al. Diagnostic efficacy of serum IL-34 level and transient elastography in predicting liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 23-26.